Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition.
Legal claims defining the scope of protection, as filed with the USPTO.
1. A method for in vivo reversion of fibrosis of the lungs in a mammalian patient, the method comprising: administering an antibody that neutralizes CD47 to the mammalian patient in a dose effective to reverse fibrosis in vivo.
2. The method of claim 1 , wherein the antibody is co-administered with an anti-VEGF agent.
3. The method of claim 1 , wherein pathogenic fibroblasts of the fibrosis have elevated levels of c-Jun.
4. The method of claim 1 , wherein the patient has been diagnosed by the method comprising: determining the presence of elevated levels of CD47 in a patient biological sample.
5. The method of claim 1 , wherein the patient has been diagnosed by the method comprising: determining the presence of elevated levels of c-Jun in a patient biological sample.
6. The method of claim 1 , wherein the patient has been analyzed after prevention or treatment by a method comprising: determining the extent of fibrosis in a patient biological sample.
7. A method for in vivo reversion of fibrosis of the lungs in a mammalian patient, the method comprising: administering an antibody that neutralizes CD47 to the mammalian patient in combination with an anti-VEGF agent, in a dose effective to reverse fibrosis in vivo.
Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.
February 28, 2018
March 29, 2022
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.